Company news
Inmed Pharmaceuticals Inc. (NASDAQ:INM) news
Inmed Pharmaceuticals Inc. news releases on 6ix. Latest, Mar 20, 2024: InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance
Press releases — page 2
InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance
March 19, 2024
InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update
February 12, 2024
InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer
February 8, 2024
InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET
January 17, 2024
InMed Pharmaceuticals Provides Business Update and Milestones for 2024
January 15, 2024
InMed Announces Results of 2023 Annual General Meeting
December 18, 2023
InMed Expands its Pharmaceutical Pipeline with INM-089 targeting the treatment of Age-Related Macular Degeneration
November 28, 2023
InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update
November 13, 2023
InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023
November 1, 2023
InMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market Under Nasdaq Rules
October 25, 2023
InMed Pharmaceuticals Inc.'s INM-901 Demonstrates Unique Pharmacological Effects in Alzheimer's Disease in Preclinical Proof-of-Concept Studies
October 23, 2023
InMed Pharmaceuticals Announces $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market under Nasdaq Rules
October 23, 2023
InMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provides Business Update
September 28, 2023
InMed Pharmaceuticals Inc. Announces Results from a Phase 2 Clinical Trial in Epidermolysis Bullosa
June 21, 2023
InMed Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update
May 14, 2023
InMed Announces Conclusion of Patient Enrollment in Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa
March 27, 2023
InMed Announces Publication of Peer-Reviewed Study Showing the Anti-Inflammatory Potential of Rare Cannabinoids in Skin Conditions
March 12, 2023
InMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Business Update
February 16, 2023
InMed Submits Form 12b-25
February 8, 2023
InMed Provides Business Update and Milestones for 2023
January 9, 2023
InMed Announces Results of 2022 Annual General Meeting
December 14, 2022
InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor
December 11, 2022
InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market
November 20, 2022
InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market
November 17, 2022
InMed Provides Update on Management Changes
November 16, 2022
InMed Pharmaceuticals Advances Neurodegenerative Disease Program with Natural Sciences and Engineering Research Council of Canada ("NSERC") Alliance Grant Funding
November 15, 2022
InMed Pharmaceuticals Reports First Quarter Fiscal 2023 Financial Results and Provides Business Update
November 10, 2022
InMed Pharmaceuticals Reports Full Year Fiscal 2022 Financial Results and Provides Business Update
September 22, 2022
InMed Pharmaceuticals Provides Update on its Core Research and Development Programs and BayMedica Business
September 7, 2022
InMed Announces Share Consolidation to Meet Nasdaq Listing Criteria
August 22, 2022
InMed Announces Changes to its Board of Directors
August 8, 2022
InMed Announces Update on Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa
July 24, 2022
InMed Announces Appointment of Chief Operating Officer
July 17, 2022
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance
July 11, 2022
InMed Announces Publication of Peer-Reviewed Study Highlighting Potential Role of Rare Cannabinoids THCV, CBC and others on Skin Conditions
June 13, 2022
InMed Launches THCV, Expanding its Portfolio of Rare Cannabinoids for the Health and Wellness Sector
June 8, 2022
InMed Pharmaceuticals Announces Closing of $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules
June 5, 2022
InMed Pharmaceuticals Announces $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules
June 1, 2022
InMed Pharmaceuticals Reports Third Quarter Fiscal 2022 Financial Results and Provides Business Update
May 12, 2022
InMed Expands Patent Portfolio with Novel Cannabinoid Analogs and Advances Collaboration Agreement with Leading Cannabinoid Research Expert
April 27, 2022
InMed Commercializes Cannabidivarin (CBDV), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector
April 20, 2022
InMed Announces Management Changes
March 16, 2022
InMed Pharmaceuticals Strengthens its Commercial Leadership Team with the Appointment of Vice President of Sales and Marketing for BayMedica
February 14, 2022
InMed Pharmaceuticals Reports Second Quarter Fiscal 2022 Financial Results and Provides Business Update
February 13, 2022
InMed Pharmaceuticals to Report Second Quarter Fiscal 2022 Financial Results and Business Update on February 15, 2022
February 9, 2022
InMed Launches Cannabicitran (CBT), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector
January 18, 2022
InMed Issues Annual Letter to Shareholders Highlighting Key Accomplishments from 2021 and Providing 2022 Outlook
January 4, 2022
InMed Pharmaceuticals Announces Publication of Peer-Reviewed Article on the Use of CBN as a Potential Treatment for Glaucoma
December 19, 2021
InMed Announces Results of 2021 Annual General Meeting
December 16, 2021
InMed Pharmaceuticals Reports First Quarter Fiscal 2022 Financial Results and Provides Business Update
November 9, 2021